Combination of Immune Checkpoint Inhibitors and Radiotherapy for Advanced Non-Small-Cell Lung Cancer and Prostate Cancer: A Meta-Analysis

<div>Forest plot for the subgroup analyses of HR of PFS for ICI+RT in NSCLC patients under 65. HR: hazard ratio; ICI: Immune checkpoint inhibitors; NSCLC: nonsmall-cell lung cancer; PFS: progression-free survival; RT: radiotherapy.</div>

Journal of Oncology

fig6

Figure 6

Figure 6: Combination of Immune Checkpoint Inhibitors and Radiotherapy for Advanced Non-Small-Cell Lung Cancer and Prostate Cancer: A Meta-Analysis 